Home 2017-06-06T14:11:03+00:00

Who We Are

pSivida is a specialty pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness.

Learn More

Our Technology

pSivida has developed three of the only four products approved by the FDA for long-term, sustained-release delivery of drug to treat chronic back-of-the-eye diseases. Approved products include: ILUVIEN®, licensed to Alimera Sciences, and RETISERT® and VITRASERT®, licensed to Bausch & Lomb. All of our approved products utilize our proprietary Durasert™ Technology platform for small molecule delivery.

Learn More

Our Pipeline

pSivida’s lead investigational new product is a three-year sustained-release implant containing fluocinolone acetonide , a corticosteroid, in late stage clinical development for the treatment of posterior uveitis. The product utilizes the proven Durasert Technology platform. The first Phase 3 study achieved its primary endpoint with high statistical significance. The second Phase 3 study results are expected first half of 2017. Filing in the EU is anticipated first half of 2017 and second half of 2017 in the U.S.

Learn More